An update to our reporting on recently-approved Alzheimer’s drugs. You may recall FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But the […]
Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it
An update on our coverage of the Alzheimer’s drug Aduhelm. And a resident of San Francisco’s drug-riddled Tenderloin District talks about the nightmarish turn she says the neighborhood has taken with the City’s permission.
After Hours: Alzheimer’s Drug Update & San Francisco’s Open-Air Drug Market (Podcast) Read More »
The biggest new hope for a blockbuster drug to cure Alzheimer’s has been mired in controversy ever since it went to market. Critics say it’s a sign of declining standards and conflicts of interest at the FDA. And now, the
FDA Adviser Dr. Caleb Alexander of John’s Hopkins talks about Aducanumab/Aduhelm: a groundbreaking Alzheimer’s treatment sent to market in one of the most controversial FDA approvals ever.
